Petra Hamerlik

Company: AstraZeneca

Job title: Director

Seminars:

12:00pm – 15:00pm Afternoon Workshop C: The DNA Damage Repair Pathway – Exploring the Various Ways That Inhibiting This Process Can Aid Glioblastoma Treatment 12:00 pm - 3:00 pm

A challenge that exists across all of pharmacology is passing the BBB. DDR inhibition shows the exciting potential to overcome this issue, so this type of treatment is able to be systemically administered. In addition to this, DDR inhibitors also have the ability to sensitize cells to other therapies like radiotherapy and immunotherapy, enhancing the…Read more

day: Pre-conference Workshop Day